MedTrace Logo

Novartis Vaccine and Diagnostics Carriage Trial

NCT01214850 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2968

Last updated 2016-04-21

Study results available
· View outcomes & findings →

Summary

The purpose of this trial was to evaluate the effect of Novartis Vaccine's Meningococcal vaccines on carriage of Neisseria meningitidis in a young adult population.

Conditions

  • N. Meningitidis Carriage

Interventions

BIOLOGICAL

Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)

BIOLOGICAL

MenACWY-CRM conjugate vaccine

BIOLOGICAL

Japanese Encephalitis vaccine

Sponsors & Collaborators

  • Novartis Vaccines

    lead INDUSTRY

Principal Investigators

  • Novartis Vaccines and Diagnostics · Novartis Vaccines

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
24 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01214850 on ClinicalTrials.gov